developed a philosophy and program of orthopedic extracorporeal shock
wave treatment which it believes maximizes the advantages of this new
technology while reducing clinical risks and enhancing cost effectiveness.
Shaped by management’s many years of clinical and administrative
experience in the urological application of both high and low energy shock
waves for kidney stones, and heavily influenced by our German orthopedic
colleagues’ experience with shock wave treatment techniques, the
Sonorex approach may be briefly summarized.
Key concepts of therapy:
of proper energy level for shock wave treatment. Although both
high and low energy may be used, Sonorex believes that the use
of low energy has significant advantages over high energy shock wave
applications in the most cases of near bone pain. These include:
a) ability to treat
patients without the necessity of regional or general
b) reduces the
clinical risk of tissue injury or bleeding into the skin, joint, or other
tissues near the area being treated
c) allows highly
individulized treatment at the exact site of pathology by allowing the
use of precise clinical focusing rather than depending upon
imaging with ultrasound, flouroscopy, or x-ray that may not adequately
identify the exact site of the problem. ( Imaging devices cannot
Within the low
energy range of energy treatment levels, the ability to adjust this
level to each patient’s tolerance adds to the concept of individualized
treatment and safety. Although the use of low energy may require more
treatment sessions (usually three) than higher energy (one to two) the
reduced cost of eliminating the anesthesia and imaging expense allows
the treatment to be more cost effective. Patients who have bone fractures
or pseudoarthroses (nonunion) should be treated with high energy and
imaging device focusing.
- Proper patient
selection. Only patients who have well localized painful areas
should be treated. These painful areas should be able to be localized
by digital pressure with the index finger. Patients with large or poorly
localized areas of near bone pain should not be treated. With proper
patient selection, 70 to 90 per cent of those treated should get significant
The Sonocur® Orthopedic Extracorporeal Shockwave system is available in Canada and other countries where regulatory approval has been obtained. The Sonocur® Basic is FDA approved in the United States for the treatment of chronic lateral epicondylitis (tennis elbow).
© 2012 Sonorex. All rights reserved. By using this service, you accept the terms of our Visitor Agreement. Please read it. The material sonorex.ca is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen.